Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.

Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K.

J Gastroenterol. 2018 May;53(5):689. doi: 10.1007/s00535-017-1409-z.

2.

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.

Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K.

J Gastroenterol. 2018 Apr;53(4):566-575. doi: 10.1007/s00535-017-1396-0. Epub 2017 Oct 20. Erratum in: J Gastroenterol. 2017 Nov 13;:.

3.

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.

Chayama K, Suzuki F, Karino Y, Kawakami Y, Sato K, Atarashi T, Naganuma A, Watanabe T, Eguchi Y, Yoshiji H, Seike M, Takei Y, Kato K, Alves K, Burroughs M, Redman R, Pugatch DL, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Kumada H.

J Gastroenterol. 2018 Apr;53(4):557-565. doi: 10.1007/s00535-017-1391-5. Epub 2017 Sep 25.

4.

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.

Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Notsumata K, Osaki Y, Nakamuta M, Takaguchi K, Saito S, Kato K, Pugatch D, Burroughs M, Redman R, Alves K, Pilot-Matias TJ, Oberoi RK, Fu B, Kumada H.

Hepatology. 2018 Feb;67(2):505-513. doi: 10.1002/hep.29510. Epub 2017 Nov 24.

5.

Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A.

DeGoey DA, Betebenner DA, Grampovnik DJ, Liu D, Pratt JK, Tufano MD, He W, Krishnan P, Pilot-Matias TJ, Marsh KC, Molla A, Kempf DJ, Maring CJ.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3627-30. doi: 10.1016/j.bmcl.2013.04.009. Epub 2013 Apr 10.

PMID:
23642966
6.

Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives.

Krueger AC, Madigan DL, Beno DW, Betebenner DA, Carrick R, Green BE, He W, Liu D, Maring CJ, McDaniel KF, Mo H, Molla A, Motter CE, Pilot-Matias TJ, Tufano MD, Kempf DJ.

Bioorg Med Chem Lett. 2012 Mar 15;22(6):2212-5. doi: 10.1016/j.bmcl.2012.01.096. Epub 2012 Feb 2.

PMID:
22342631
7.

Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.

Chen CM, He Y, Lu L, Lim HB, Tripathi RL, Middleton T, Hernandez LE, Beno DW, Long MA, Kati WM, Bosse TD, Larson DP, Wagner R, Lanford RE, Kohlbrenner WE, Kempf DJ, Pilot-Matias TJ, Molla A.

Antimicrob Agents Chemother. 2007 Dec;51(12):4290-6. Epub 2007 Oct 1.

8.

Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759.

Lu L, Mo H, Pilot-Matias TJ, Molla A.

Antimicrob Agents Chemother. 2007 Jun;51(6):1889-96. Epub 2007 Mar 19.

9.

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.

Lu L, Pilot-Matias TJ, Stewart KD, Randolph JT, Pithawalla R, He W, Huang PP, Klein LL, Mo H, Molla A.

Antimicrob Agents Chemother. 2004 Jun;48(6):2260-6.

10.

Prevalence of TT virus infection in US blood donors and populations at risk for acquiring parenterally transmitted viruses.

Desai SM, Muerhoff AS, Leary TP, Erker JC, Simons JN, Chalmers ML, Birkenmeyer LG, Pilot-Matias TJ, Mushahwar IK.

J Infect Dis. 1999 May;179(5):1242-4.

PMID:
10191229
11.

Molecular and biophysical characterization of TT virus: evidence for a new virus family infecting humans.

Mushahwar IK, Erker JC, Muerhoff AS, Leary TP, Simons JN, Birkenmeyer LG, Chalmers ML, Pilot-Matias TJ, Dexai SM.

Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3177-82.

12.

GB virus C E2 glycoprotein: expression in CHO cells, purification and characterization.

Surowy TK, Leary TP, Carrick RJ, Knigge MF, Pilot-Matias TJ, Heynen C, Gutierrez RA, Desai SM, Dawson GJ, Mushahwar IK.

J Gen Virol. 1997 Aug;78 ( Pt 8):1851-9.

PMID:
9266979
13.

Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker.

Pilot-Matias TJ, Carrick RJ, Coleman PF, Leary TP, Surowy TK, Simons JN, Muerhoff AS, Buijk SL, Chalmers ML, Dawson GJ, Desai SM, Mushahwar IK.

Virology. 1996 Nov 15;225(2):282-92.

14.

Sequence heterogeneity within the 5'-terminal region of the hepatitis GB virus C genome and evidence for genotypes.

Muerhoff AS, Simons JN, Leary TP, Erker JC, Chalmers ML, Pilot-Matias TJ, Dawson GJ, Desai SM, Mushahwar IK.

J Hepatol. 1996 Sep;25(3):379-84.

PMID:
8895018
15.

Prevalence studies of GB virus-C infection using reverse transcriptase-polymerase chain reaction.

Dawson GJ, Schlauder GG, Pilot-Matias TJ, Thiele D, Leary TP, Murphy P, Rosenblatt JE, Simons JN, Martinson FE, Gutierrez RA, Lentino JR, Pachucki C, Muerhoff AS, Widell A, Tegtmeier G, Desai S, Mushahwar IK.

J Med Virol. 1996 Sep;50(1):97-103.

PMID:
8890047
16.

Identification of antigenic regions in the GB hepatitis viruses GBV-A, GBV-B, and GBV-C.

Pilot-Matias TJ, Muerhoff AS, Simons JN, Leary TP, Buijk SL, Chalmers ML, Erker JC, Dawson GJ, Desai SM, Mushahwar IK.

J Med Virol. 1996 Apr;48(4):329-38.

PMID:
8699165
17.

Sequence and genomic organization of GBV-C: a novel member of the flaviviridae associated with human non-A-E hepatitis.

Leary TP, Muerhoff AS, Simons JN, Pilot-Matias TJ, Erker JC, Chalmers ML, Schlauder GG, Dawson GJ, Desai SM, Mushahwar IK.

J Med Virol. 1996 Jan;48(1):60-7.

PMID:
8825712
18.

Consensus oligonucleotide primers for the detection of GB virus C in human cryptogenic hepatitis.

Leary TP, Muerhoff AS, Simons JN, Pilot-Matias TJ, Erker JC, Chalmers ML, Schlauder GG, Dawson GJ, Desai SM, Mushahwar IK.

J Virol Methods. 1996 Jan;56(1):119-21.

PMID:
8690760
19.

Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis.

Muerhoff AS, Leary TP, Simons JN, Pilot-Matias TJ, Dawson GJ, Erker JC, Chalmers ML, Schlauder GG, Desai SM, Mushahwar IK.

J Virol. 1995 Sep;69(9):5621-30.

20.

Origin of GB-hepatitis viruses.

Schlauder GG, Pilot-Matias TJ, Gabriel GS, Simons JN, Muerhoff AS, Dawson GJ, Mushahwar IK.

Lancet. 1995 Aug 12;346(8972):447-8. No abstract available.

PMID:
7623597
21.

Isolation of novel virus-like sequences associated with human hepatitis.

Simons JN, Leary TP, Dawson GJ, Pilot-Matias TJ, Muerhoff AS, Schlauder GG, Desai SM, Mushahwar IK.

Nat Med. 1995 Jun;1(6):564-9.

PMID:
7585124
22.

Molecular and serologic analysis in the transmission of the GB hepatitis agents.

Schaluder GG, Dawson GJ, Simons JN, Pilot-Matias TJ, Gutierrez RA, Heynen CA, Knigge MF, Kurpiewski GS, Buijk SL, Leary TP, et al.

J Med Virol. 1995 May;46(1):81-90.

PMID:
7623012
23.

Identification of two flavivirus-like genomes in the GB hepatitis agent.

Simons JN, Pilot-Matias TJ, Leary TP, Dawson GJ, Desai SM, Schlauder GG, Muerhoff AS, Erker JC, Buijk SL, Chalmers ML, et al.

Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3401-5.

24.
25.
26.

High-level expression of recombinant human FK-binding protein from a fusion precursor.

Edalji R, Pilot-Matias TJ, Pratt SD, Egan DA, Severin JM, Gubbins EG, Petros AM, Fesik SW, Burres NS, Holzman TF.

J Protein Chem. 1992 Jun;11(3):213-23.

PMID:
1382438
27.

Glucocorticoids regulate surfactant protein synthesis in a pulmonary adenocarcinoma cell line.

O'Reilly MA, Gazdar AF, Clark JC, Pilot-Matias TJ, Wert SE, Hull WM, Whitsett JA.

Am J Physiol. 1989 Dec;257(6 Pt 1):L385-92.

PMID:
2610267
28.

In vitro translation, post-translational processing and secretion of pulmonary surfactant protein B precursors.

O'Reilly MA, Weaver TE, Pilot-Matias TJ, Sarin VK, Gazdar AF, Whitsett JA.

Biochim Biophys Acta. 1989 May 10;1011(2-3):140-8.

PMID:
2713400
29.

Structure and organization of the gene encoding human pulmonary surfactant proteolipid SP-B.

Pilot-Matias TJ, Kister SE, Fox JL, Kropp K, Glasser SW, Whitsett JA.

DNA. 1989 Mar;8(2):75-86.

PMID:
2924687
30.

Two SP-C genes encoding human pulmonary surfactant proteolipid.

Glasser SW, Korfhagen TR, Perme CM, Pilot-Matias TJ, Kister SE, Whitsett JA.

J Biol Chem. 1988 Jul 25;263(21):10326-31.

Supplemental Content

Loading ...
Support Center